HIV Drugs Market
完整報告名稱與涵蓋範圍
HIV Drugs Market Size, Share & Trends Analysis Report, By Drug Class (Integrase Inhibitor-Based Regimens, Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors, Protease Inhibitors, Long-Acting Injectables, Capsid Inhibitors and Novel Mechanisms), By Application (HIV Treatment, Pre-Exposure Prophylaxis), By Dosing Regimen (Daily Oral Single-Tablet Regimens, Long-Acting Injectable Regimens), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The HIV drugs market covers antiretroviral medicines for treatment and prevention of HIV infection, including integrase inhibitor-based single-tablet regimens, reverse transcriptase and protease inhibitors, long-acting injectable treatment and pre-exposure prophylaxis regimens, capsid inhibitors and generics supplied to low- and middle-income countries. Diagnostics, vaccines in development and cure research are outside the revenue scope.
Treatment has consolidated around highly effective integrase-based single-tablet regimens, so growth now comes from long-acting injectables that replace daily pills, from twice-yearly prophylaxis that could transform prevention uptake and from two-drug regimens that reduce lifetime drug exposure. Sponsors are developing weekly oral and yearly injectable options, while generic manufacturers supply the majority of patients worldwide through donor-funded programs whose budgets face pressure. Ageing of the treated population, adherence and resistance considerations and the distribution logistics of injectable regimens shape product mix and pricing.
North America and Europe account for most value, whereas sub-Saharan Africa and Asia represent the bulk of treated patients supplied largely by Indian generic manufacturers under licensing arrangements. Competition is concentrated between two innovator franchises, complemented by generic producers and emerging Chinese developers of novel agents.
The InsightAce study includes revenue forecasts in US$ for all drug class, application, dosing regimen and distribution channel and regional segments across 2026-2035, segment-level trend analysis, competitive positioning assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global HIV Drugs Market Snapshot
Chapter 4. Global HIV Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. Drug Class & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Class:
5.2.1. Integrase Inhibitor-Based Regimens
5.2.2. Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors
5.2.3. Protease Inhibitors
5.2.4. Long-Acting Injectables
5.2.5. Capsid Inhibitors and Novel Mechanisms
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. Application & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
6.2.1. HIV Treatment
6.2.2. Pre-Exposure Prophylaxis
Chapter 7. Market Segmentation 3: By Dosing Regimen Estimates & Trend Analysis
7.1. Dosing Regimen & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Dosing Regimen:
7.2.1. Daily Oral Single-Tablet Regimens
7.2.2. Long-Acting Injectable Regimens
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital and Public Health Pharmacies
8.2.2. Retail and Specialty Pharmacies
Chapter 9. HIV Drugs Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Gilead Sciences, Inc.
11.2. ViiV Healthcare (GSK plc)
11.3. Johnson & Johnson
11.4. Merck & Co., Inc.
11.5. Theratechnologies Inc.
11.6. Cipla Ltd.
11.7. Aurobindo Pharma Ltd.
11.8. Hetero Labs Ltd.
11.9. Laurus Labs Ltd.
11.10. Viatris Inc.
11.11. Sun Pharmaceutical Industries Ltd.
11.12. Shanghai Aidea Pharmaceutical Co., Ltd.
11.13. Frontier Biotechnologies Inc.
11.14. Emcure Pharmaceuticals Ltd.
11.15. Lupin Ltd.
圖表清單 List of Tables & Figures
Table 1. Global HIV Drugs Market Revenue Forecast by Drug Class, 2026-2035 (US$ Mn)
Figure 1. Global HIV Drugs Market Segmentation Overview
Table 2. Global HIV Drugs Market Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 2. Global HIV Drugs Market Share by Drug Class, 2026 & 2035
Table 3. Global HIV Drugs Market Revenue Forecast by Dosing Regimen, 2026-2035 (US$ Mn)
Figure 3. Regimen Shift from Daily Oral Tablets to Long-Acting Injectables, 2026-2035
Table 4. Global HIV Drugs Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Global HIV Drugs Market Share by Application, 2026 & 2035
Table 5. North America HIV Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Pre-Exposure Prophylaxis Uptake Scenarios with Twice-Yearly and Yearly Options
Table 6. Europe HIV Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific HIV Drugs Growth Opportunity Analysis
Table 7. Asia Pacific HIV Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Global Treated Population and Funding Sources by Region
Table 8. Latin America HIV Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key HIV Drugs Market Participants
Table 9. Middle East & Africa HIV Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們